IOVA · NASDAQ · STOCK
Iovance Biotherapeutics, Inc.
$6.49
52W $1.76 – $6.92
67/100
$2.90B
-9.3
0.70
Is IOVA Bullish or Bearish?
Bullish.
Innellis AI committee rates Iovance Biotherapeutics, Inc. (IOVA) Buy with a composite score of 67/100
, based on 6 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +8.48 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -11.52 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 58.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
67/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 11%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -40.5% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.5% YoY -- genuine top-line momentum
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 79 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 58.1% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 21 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
79.2
Overbought
MACD Histogram
0.187
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.98
Inside Bands
Price vs Moving Averages
EMA 9
$5.60
Above
EMA 21
$5.11
Above
EMA 50
$4.63
Above
EMA 200
$3.76
Above
Fundamental Analysis
Valuation
87
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-9.3×
P/B Ratio
3.97×
PEG Ratio
-0.15
Dividend Yield
0.00%
52W High
$6.92
52W Low
$1.76
Quality & Growth
ROE
-5596.7%
ROA
-4281.6%
Gross Margin
11630.0%
Operating Margin
-9271.9%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -9.3 (inexpensive relative to a 15-40x range); Price-to-book of 4.0x; PEG ratio of -0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -56.0%; Return on assets of -42.8%; Net margin of -89.1%; Gross margin of 116.3%; Current ratio of 4.35 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is negative (-0.66); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full IOVA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →